Kytril (Granisetron)

Granisetron works as a selective antagonist of the 5‑HT3 receptor. It blocks serotonin from binding to these receptors in the chemoreceptor trigger zone of the brain and on vagal afferents in the gastrointestinal tract, thereby interrupting the neural pathways that trigger nausea and vomiting.

The specific dose of Kytril is determined by the prescribing clinician based on the patient’s condition, treatment protocol, and other clinical factors. Healthcare professionals follow established guidelines for chemotherapy or postoperative antiemetic regimens, and the exact amount is individualized for each patient.

Safety data for granisetron during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To order Kytril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Both Kytril (granisetron) and ondansetron belong to the 5‑HT3 antagonist class, but granisetron has a longer half‑life and may provide more sustained antiemetic control with fewer dosing intervals. Ondansetron is often available in oral and IV forms, whereas Kytril is supplied as an injectable solution, making it suitable for rapid IV administration in acute settings.

Kytril should be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If refrigeration is unavailable for a short period, the product may be kept at controlled room temperature, but it must be returned to the recommended temperature promptly.

Kytril is administered intravenously as a sterile solution. The dose is typically given as a slow IV push or infusion over a few minutes, depending on the clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV drug delivery and patient monitoring.

The most serious risks include severe allergic reactions such as anaphylaxis, cardiac arrhythmias due to QT‑interval prolongation, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for signs of hypersensitivity, cardiac rhythm changes, and severe constipation or intestinal obstruction.

Kytril should not be used in individuals with a known hypersensitivity to granisetron or any component of the formulation. It is also contraindicated in patients with a history of prolonged QT interval or those taking multiple QT‑prolonging medications without appropriate cardiac monitoring. Clinicians should assess each patient’s medical history before prescribing.